PURPOSE: We aimed at assessing the overall efficacy of angiogenesis inhibitor (AI)-containing regimens in the treatment of advanced @entity1149 ( @entity1149 ) according to histological types. METHODS: Studies from PubMed and Web of Science, and abstracts presented at American Society of Clinical Oncology (ASCO) meeting up to October 31, 2014 were searched to identify relevant studies. Eligible studies included prospective @entity23 ( @entity23 ) evaluating AIs in advanced @entity1149 with survival data according to @entity1 ' histologies. The endpoints were @entity1349 ( @entity1349 ) and progression-free survival (PFS). Statistical analyses were conducted by using either random effects or fixed effect models according to the heterogeneity of included studies. RESULTS: A total of 10,035 @entity1 with advanced @entity1149 from 13 @entity23 were identified for analysis. The pooled results demonstrated that AI-containing regimens significantly improved the PFS (HR, 0.84, 95% confidence interval (CI): 0.78-0.91, P<0.001) and @entity1349 (HR, 0.92, 95% CI: 0.85-0.99, P=0.017) in @entity2220 when compared to non-AI-containing regimens. Additionally, there was a significantly improved PFS (HR, 0.87, 95% CI: 0.77-0.98, P=0.027) for AI-containing regimens in @entity957 , but it did not translated into @entity1349 benefit (HR, 1.02, 95% CI: 0.92-1.15, P=0.68). For @entity1149 @entity1 with other histological types, the use of AIs did not significantly improve PFS (HR, 0.90, 95% CI: 0.75-1.09, P=0.27) and @entity1349 (HR, 0.90, 95% CI: 0.76-1.08, P=0.19). CONCLUSION: The findings of this study suggest that the addition of AIs to the treatment therapies for @entity1 with @entity2220 offers improved survival benefits. Prospective clinical trials investigating the role of AIs in this setting are recommended.

The impact of histological types on the efficacy of angiogenesis inhibitors in the treatment of advanced @entity1149 : a meta-analysis of XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity957 :: ('MESH:D002294', 'Disease') :: ['squamous cell lung carcinoma'] @entity1149 :: ('MESH:D002289', 'Disease') :: ['NSCLC', 'non-small-cell lung cancer'] @entity23 :: ('MESH:D007174', 'Disease') :: ['randomized controlled trials', 'RCTs'] @entity2220 :: ('MESH:C538231', 'Disease') :: ['lung adenocarcinoma'] @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'overall survival']
@entity23 :: (MESH:D007174,Disease) :: ['randomized controlled trials']
